Clinical trials: Advanced Malignant Tumor
Advanced Solid Tumor
CVL006 Combination Therapy in Advanced Solid Tumors
This study is a multi-center, open-label, dose-escalation and dose-optimized phase I/II clinical trial. Objective: To determine the safety, tolerability, PK characteristics and preliminary efficacy data of CVL006 combined with…
- Trial name
- CVL006-T1002 (NCT07157956)
- Testing
- CVL006 combined with pemetrexed and carboplatin, CVL006 in combination with SKB264, CVL006 in combination with DS-8201
- Where
- China
- Volunteers
- 318 people
- Sponsor
- Convalife (Shanghai) Co., Ltd.
Advanced Solid Tumor, Adult Disease
A Study Evaluating Safety and Therapeutic Activity of ANV419 in Patients with Advanced Cancer.
The purpose of this study is to test the safety and efficacy of ANV419 (single agent) and in combination with ipilimumab in patients with relapsed/refractory advanced solid tumors.
- Conditions
- Advanced Solid Tumor, Adult Disease, Lung Cancer
- Trial name
- ANV419-001 (NCT04855929)
- Testing
- ANV419, Ipilimumab
- Where
- 5 sites in Spain, Switzerland and 1 more
- Volunteers
- 55 people
- Sponsor
- Anaveon AG
Cervical Cancer, Endometrial Cancer
Capecitabine and Radiation Therapy in Treating Patients With Locally Advanced Cervical Cancer or Other Pelvic Cancer
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer
- Trial name
- NCT00118300
- Testing
- capecitabine, brachytherapy, radiation therapy
- Where
- 2 sites in United States
- Sponsor
- Case Comprehensive Cancer Center
Malignant Melanoma
Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients
An observational single center study designed to identify response-related biomarkers of anti-programmed death 1 (PD-1) therapy to advanced melanoma patients and to investigate if vitamin D levels are related to treatment…
- Trial name
- NCT03197636
- Testing
- Pembrolizumab
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aarhus University Hospital
Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Liver Cancer
Study of Metatinib Tromethamine Tablet
This is an open-label, multicenter study designed to assess the safety, tolerability, preliminary efficacy and pharmacokinetics of Metatinib Tromethamine tablet in patients with advanced or metastatic gastric cancer, liver…
- Conditions
- Advanced or Metastatic Gastric Cancer, Advanced or Metastatic Liver Cancer, Advanced or Metastatic CRC, Advanced or Metastatic Non Squamous NSCLC
- Trial name
- NCT02650375
- Testing
- Metatinib Tromethamine
- Where
- 3 sites in China
- Volunteers
- 24 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Tumor
IMM40H Phase I Dose Escalation and Expansion
This is first-in-human, open-label, multi-center, dose-escalation (phase Ia) and cohort expansion (phase Ib) phase I study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamic, immunogenicity, and antitumor…
- Trial name
- NCT05549557
- Testing
- IMM40H
- Volunteers
- 16 people
- Sponsor
- ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Neoplasms
Effect of Regorafenib on Digoxin and Rosuvastatin in Patients With Advanced Solid Malignant Tumors.
Evaluate the effect of regorafenib on the pharmacokinetics of digoxin (P-gp substrate : P-glycoprotein) and rosuvastatin (BCRP substrate: Breast cancer resistant protein) by comparing their Area under time curve (AUC(0-24)) and…
- Trial name
- NCT02106845
- Testing
- Digoxin, Rosuvastatin, Regorafenib (Stivarga, BAY73-4506)
- Where
- 5 sites in Germany, Hungary
- Volunteers
- 42 people
- Sponsor
- Bayer
Solid Tumor, Androgen Receptor Gene Overexpression
Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive Glioblastoma
This study's purpose is to facilitate and expedite the clinical testing of SEVI-D in a population with advanced GBM that are androgen receptor (AR) positive.
- Trial name
- START (NCT03600467)
- Testing
- SEVI-D (Seviteronel in combination with dexamthasone)
- Where
- Australia
- Volunteers
- 4 people
- Sponsor
- St Vincent's Hospital, Sydney
NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer)
A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.
This is a multicenter, open-label, randomized (1:1) trial designed to evaluate whether ctDNA-guided interruption of immune-checkpoint inhibitor (ICI) therapy provides comparable survival to standard of care (SoC) continuous ICI…
- Conditions
- NSCLC (Advanced Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Cancer), NSCLC (Non-small Cell Lung Carcinoma), NSCLC
- Trial name
- SIGNAL-IO 301 (NCT07689812)
- Testing
- Signatera Genome ultra-sensitive ctDNA blood test
- Volunteers
- 920 people
- Sponsor
- Natera, Inc.
Advanced Solid Tumor, SCLC(Small Cell Lung Cancer) or LCNEC (Large Cell Neuroendocrine Carcinoma)
A Study of FZ-AD005 in Patients With Advanced Solid Tumors
A First-in-Human, Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of FZ-AD005 in Patients with Advanced Solid Tumors.
- Trial name
- NCT06424665
- Testing
- FZ-AD005
- Where
- 3 sites in China
- Volunteers
- 162 people
- Sponsor
- Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Advanced Solid Tumor, Advanced/Metastatic Colorectal Cancer
Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors
This study evaluates the safety, tolerability, preliminary efficacy and pharmacokinetics of Simmitecan in patients with advanced solid tumors and Simmitecan, 5-fluorouracil and Leucovorin Calcium,thalidomide in patients with…
- Trial name
- NCT02870036
- Testing
- Simmitecan, 5-fluorouracil and Leucovorin Calcium, Thalidomide
- Where
- 9 sites in China
- Volunteers
- 243 people
- Sponsor
- Haihe Biopharma Co., Ltd.
Hepatocellular Carcinoma, Portal Vein Tumor Thrombus
TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT
Hepatocellular carcinoma (HCC) with main trunk portal vein tumor thrombus (PVTT) has poor prognosis. The main lethiferous factor is the upper gastrointestinal hemorrhage by PVTT-related portal hypertension, then the second is the…
- Conditions
- Hepatocellular Carcinoma, Portal Vein Tumor Thrombus, Systemic Therapy
- Trial name
- NCT06622031
- Testing
- Transjugular intrahepatic portosystemic shunt, Lenvatinib, PD-1 inhibitor
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Sun Yat-sen University
Metastatic Cancer, Soft Tissue Sarcoma
A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors
This is a Phase I/IIa, multicenter, open-label, consecutive cohorts, dose-escalation study of BT-001 with repeated IT administrations alone and in combination with IV infusions of pembrolizumab.
- Conditions
- Metastatic Cancer, Soft Tissue Sarcoma, Merkel Cell Carcinoma, Melanoma
- Trial name
- NCT04725331
- Testing
- BT-001, Pembrolizumab [KEYTRUDA®]
- Where
- 5 sites in Belgium, France
- Volunteers
- 31 people
- Sponsor
- Transgene
Advanced Solid Tumor
Study of SGN1 Administered Via Intratumoral Injection in Patients With Advanced Solid Tumor
Objectives: To characterize safety, tolerability, MTD and OBD of intratumoral injection of SGN1 in patients with advanced solid tumors, and to preliminarily investigate the efficacy and safety of SGN1 in specific tumor subtypes.
- Trial name
- NCT05103345
- Testing
- SGN1
- Where
- 4 sites in China, Taiwan
- Volunteers
- 70 people
- Sponsor
- Guangzhou Sinogen Pharmaceutical Co., Ltd
Neoplasms, Lymphoma
An Early Phase I Study of IPdR Absorption, Metabolism, and Safety in Patients With Advanced Solid Tumors and Lymphomas
Background: The experimental drug IPdR is broken down in the body to IdUrd, which has been given to patients to find out if it can improve radiation therapy.
- Trial name
- NCT01240577
- Testing
- IPdR
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Advanced Solid Tumor
NL-201 Monotherapy and in Combination With Pembrolizumab in Patients With Relapsed or Refractory Cancer
Parts 1 and 2 The primary purpose of this study is to understand the safety of NL-201 when given intravenously as monotherapy in patients with advanced cancer to evaluate tolerability and to identify a recommended dose and…
- Trial name
- NCT04659629
- Testing
- NL-201, Pembrolizumab Injection [Keytruda]
- Where
- 8 sites in United States, Australia and 1 more
- Volunteers
- 59 people
- Sponsor
- Neurogene Inc.
Metastatic Tumor, Renal Cell Carcinoma
Clinical Study of CD70-targeted CAR-T Therapy for Advanced/Advanced Renal Cancer
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with advanced/metastatic renal cell carcinoma, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Metastatic Tumor, Renal Cell Carcinoma, Advanced Cancer
- Trial name
- NCT05420519
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Advanced Malignant Solid Tumours
A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects With Advanced Malignant Solid Tumour
This study is a Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Initial Efficacy of JS212 in Subjects with Advanced Malignant Solid Tumour.
- Trial name
- NCT06888830
- Testing
- JS212 for Injection
- Where
- China
- Volunteers
- 374 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma
Oral Hedgehog Inhibitors in the Treatment of Basal Cell Carcinoma in the Netherlands: a Prospective Registration Study
Background: Oral hedgehog inhibitors vismodegib and sonidegib have been used for the treatment of locally advanced (laBCC), metastatic basal cell carcinoma (mBCC) and in basal cell nevus syndrome (BCNS) patients.
- Conditions
- Basal Cell Carcinoma, Locally Advanced Basal Cell Carcinoma, Metastatic Basal Cell Carcinoma, Gorlin Syndrome
- Trial name
- NCT05463757
- Testing
- Vismodegib, Sonidegib
- Where
- 8 sites in Netherlands
- Volunteers
- 80 people
- Sponsor
- Maastricht University Medical Center
Advanced Cancer, Metastatic Cancer
Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
- Conditions
- Advanced Cancer, Metastatic Cancer, Malignant Neoplasm of Lung
- Trial name
- NCT05853575
- Testing
- Adagrasib
- Where
- 98 sites in United States, Brazil and 16 more
- Volunteers
- 200 people
- Sponsor
- Mirati Therapeutics Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.